Moderna filed regulatory applications in the US, EU, Canada and Australia seeking approval of mRNA‑1010, its seasonal influenza vaccine for people 50 and older. The company pitched the shot as a strategic revenue driver as it rebuilds growth after COVID and RSV setbacks, and said geographic approvals would support its respiratory disease franchise expansion. Phase 3 data showed mRNA‑1010 reduced influenza illness by about 27% versus marketed vaccines in people 50+, with similar results in those 65 and older; adverse events were mostly mild and comparable to existing shots. Moderna emphasized mRNA technology’s speed in strain matching and forecasted the vaccine as a contributor to its path back to profitability.